Bioatla

Bioatla PP&E per Employee

The PP&E per Employee of Bioatla (BCAB) as of Nov 18, 2026 is 41,333.33 USD. In the previous year, PP&E per Employee was 105,696.97 USD — a change of -60.89% (lower).

PP&E per Employee

41,333.33USD

YoY

-60.89%

Last updated:

PP&E per Employee of Bioatla is 2022 41,333.33 USD. PP&E per Employee of Bioatla was 2021 105,696.97 USD. It decreases by -60.89% lower compared to the previous year.

The Bioatla PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2018
58,757.58 USD
Jan 1, 2019
70,833.33 USD
Jan 1, 2020
62,151.52 USD
Jan 1, 2021
105,696.97 USD
Jan 1, 2022
41,333.33 USD
The Bioatla PP&E per Employee history
YEARPP&E per EmployeeYoY
41,333.33USD-60.89%
105,696.97USD+70.06%
62,151.52USD-12.26%
70,833.33USD+20.55%
58,757.58USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioatla stock

PP&E per Employee of Bioatla is 41,333.33 USD in 2022.

PP&E per Employee of Bioatla changed from 105,696.97 USD to 41,333.33 USD, representing a -60.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Bioatla since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Bioatla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Bioatla

All Key Metrics — Bioatla